A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies

NCT07255898 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

33

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma
Hematologic Malignancies

Interventions

DRUG: BL-M24D1

Sponsor

Sichuan Baili Pharmaceutical Co., Ltd.

Collaborators

[object Object]